Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus PAPA DEINE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus PAPA DEINE 3.
INVAGESIC vs PAPA-DEINE #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Acetaminophen produces analgesia and antipyresis via central COX-2 inhibition and activation of descending serotonergic pathways. Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits ascending pain pathways and alters pain perception.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 12 tablets in 24 hours. Each tablet contains acetaminophen 300 mg, codeine phosphate 30 mg.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Codeine: 2.5-3 hours; Acetaminophen: 2-3 hours; Morphine (active metabolite): 2-3 hours. In hepatic impairment, codeine half-life may extend to 4-6 hours.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Primarily renal (90% as glucuronide conjugates, 10% as morphine, codeine, and norcodeine). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination